1 The excitatory events that trigger
myotonic action potentials in the absence of stabilizing
2 slow afterdepolarization (AfD) that triggers
myotonic action potentials.
3 vealed the absence of the exons 15 and 16 in
myotonic animals.
4 on of the linear fragment of pumiliotoxin B (
myotonic,
cardiotonic) and enantioselective synthesis an
5 ncluding muscle histological morphology, and
myotonic discharges and heart conduction abnormalities,
6 n shows delayed relaxation, and there are no
myotonic discharges at electromyography, we recommend di
7 tal limbs of Tg26-hDMPK showed myopathy with
myotonic discharges coupled with deficit in sarcolemmal
8 e sodium channel alpha-subunit, resulting in
myotonic discharges in skeletal muscle of the lower urin
9 Myotonic discharges were more common in statin-associate
10 duction in the CUG(exp) mRNA, a reduction in
myotonic discharges, a shift toward adult pre-mRNA splic
11 ty and deactivation kinetics, and eliminated
myotonic discharges.
12 The
myotonic dystrophies (DM) are human diseases in which th
13 PURPOSE OF REVIEW: The
myotonic dystrophies (DM1 and DM2) are the paradigm for
14 known RNA-mediated disorders, including the
myotonic dystrophies and fragile X tremor ataxia syndrom
15 tor protein that plays a pivotal role in the
Myotonic Dystrophies and Huntington's Disease, and sever
16 Myotonic dystrophies are the most common, comprising 28.
17 The pathomechanism for the
myotonic dystrophies is not well understood and the role
18 ansions of noncoding CUG and CCUG repeats in
myotonic dystrophies type 1 (DM1) and DM2 cause complex
19 Myotonic dystrophies type 1 (DM1) and type 2 (DM2) are n
20 Myotonic dystrophies type 1 and type 2 are progressive m
21 tive approach to screening and management of
myotonic dystrophies type 1 and type 2 requires a multid
22 c mechanisms that have been proposed for the
myotonic dystrophies, the clinical and molecular feature
23 e splicing and polyadenylation in congenital
myotonic dystrophy (CDM).
24 Myotonic dystrophy (DM) is a genetic disorder caused by
25 Myotonic dystrophy (DM) is a multi-system neuromuscular
26 Myotonic dystrophy (DM) is a multisystemic disease cause
27 Myotonic dystrophy (DM) is caused by a CTG expansion in
28 Myotonic dystrophy (DM) is caused by a triplet repeat ex
29 Myotonic dystrophy (DM) is caused by either an untransla
30 Myotonic dystrophy (DM) is caused by the expression of m
31 a topic of intense study due to its role in
myotonic dystrophy (DM) pathogenesis.
32 The RNA-mediated disease model for
myotonic dystrophy (DM) proposes that microsatellite C(C
33 Myotonic dystrophy (DM) type 1 is associated with an exp
34 (MBNL) protein family has been implicated in
myotonic dystrophy (DM), a specific function for these p
35 In
myotonic dystrophy (DM), expression of RNA containing ex
36 t roles in muscle and eye development and in
myotonic dystrophy (DM), in which expanded CUG or CCUG r
37 foci by C(C)UG microsatellite expansions in
myotonic dystrophy (DM), is essential for normal thymus
38 proposed first for the neuromuscular disease
myotonic dystrophy (DM), which is associated with the ex
39 Myotonic dystrophy (DM)--the most common form of muscula
40 pathogenic event in the RNA-mediated disease
myotonic dystrophy (DM).
41 is a key player in the disease mechanism of
myotonic dystrophy (DM).
42 tal muscle development and are implicated in
myotonic dystrophy (DM).
43 UGn RNA in the induction of stress in type 1
myotonic dystrophy (DM1) cells and in the stress-mediate
44 Myotonic dystrophy (DM1) is a highly variable, multi-sys
45 Type I
myotonic dystrophy (DM1) is caused by a triplet repeat e
46 Myotonic dystrophy (DM1) is caused by an expansion of CU
47 In
myotonic dystrophy (DM1), both inactivation of musclebli
48 Myotonic dystrophy (DM1), the most common muscular dystr
49 rections for many genetic diseases including
myotonic dystrophy (DM1).
50 ein implicated in the pathogenesis of type I
myotonic dystrophy (DM1).
51 ated with expanded repeat sequences, such as
myotonic dystrophy (DM1).
52 In
myotonic dystrophy (dystrophia myotonica [DM]), an incre
53 Myotonic dystrophy (dystrophia myotonica, DM) is a multi
54 ls have been implicated in schizophrenia and
myotonic dystrophy (MD), and both conditions carry an in
55 Myotonic dystrophy 1 (DM1) is a multi-system disorder ch
56 Myotonic dystrophy 1 (DM1) is a multisystemic disease ca
57 In
myotonic dystrophy 1 (DM1), aggregation of the mutant DM
58 f skeletal muscle pathology in patients with
Myotonic Dystrophy 1 (DM1).
59 ts for Duchenne MD, various limb girdle MDs,
myotonic dystrophy 1, facioscapulohumeral MD, dysferlino
60 Myotonic dystrophy 2 (DM2) is a multisystem skeletal mus
61 Myotonic dystrophy 2 (DM2) is an autosomal dominant, mul
62 the results with those of four patients with
myotonic dystrophy and 12 healthy individuals.
63 ween the pathogenic RNA repeat expansions of
myotonic dystrophy and MBNL1.
64 Using a cell culture model of
myotonic dystrophy and myotonic dystrophy patient tissue
65 ls are key players in both the human disease
myotonic dystrophy and the regulation of alternative spl
66 nic mouse model to show that derangements of
myotonic dystrophy are reversed by a morpholino antisens
67 This process is dysregulated in
myotonic dystrophy because MBNL proteins are sequestered
68 for a therapeutic strategy for treatment of
myotonic dystrophy by ablating or silencing expression o
69 sis might have a clinically relevant role in
myotonic dystrophy cardiac conduction defects and pathol
70 The genetic lesion in
myotonic dystrophy does not eliminate an essential muscl
71 Research on
myotonic dystrophy has led to the recognition of a novel
72 unction is a prominent cause of mortality in
myotonic dystrophy I (DM1), a disease where expanded CUG
73 in the development of RNA splice defects in
myotonic dystrophy I (DM1), we purified RNA-independent
74 Therapeutic development for
myotonic dystrophy is moving rapidly with the developmen
75 RECENT FINDINGS: RNA toxicity in
myotonic dystrophy is now associated with bi-directional
76 In
myotonic dystrophy it is the RNA rather than protein pro
77 roteins HSP20, HSP25, alphaB-crystallin, and
myotonic dystrophy kinase binding protein (MKBP) may reg
78 MRCK (
myotonic dystrophy kinase-related Cdc42 binding kinase),
79 Myotonic dystrophy kinase-related Cdc42-binding kinase (
80 ation and invasion by binding and activating
myotonic dystrophy kinase-related CDC42-binding kinase a
81 Caspase-mediated cleavage of
myotonic dystrophy kinase-related CDC42-binding kinase-a
82 cell culture model of myotonic dystrophy and
myotonic dystrophy patient tissue, we have evidence that
83 L1, a splicing factor that is sequestered in
myotonic dystrophy patients by binding to expanded r(CUG
84 In human cells from
myotonic dystrophy patients, treatment with 5-aza-CdR st
85 e variant CaV1.1e in the skeletal muscles of
myotonic dystrophy patients.
86 sed Znf9 and Clc1 expression and rescued the
myotonic dystrophy phenotype in Znf9+/- mice.
87 e Znf9 haploinsufficiency contributes to the
myotonic dystrophy phenotype in Znf9+/- mice.
88 e basis for a new type of instability of the
myotonic dystrophy protein kinase (DMPK) gene in patient
89 Myotonic dystrophy protein kinase (DMPK), a muscle- and
90 G)n tract in the 3' UTR of the gene encoding
myotonic dystrophy protein kinase (DMPK), which results
91 ' untranslated region of the gene coding for
myotonic dystrophy protein kinase (DMPK).
92 Abnormal expression of human
myotonic dystrophy protein kinase (hDMPK) gene products
93 -coil domain reminiscent of eukaryotic DMPK (
Myotonic Dystrophy Protein Kinase) family kinases such a
94 By this mechanism, effects of
myotonic dystrophy repeat expansions impact many differe
95 human samples from patients with congenital
myotonic dystrophy type 1 (CDM1) and spinal muscular atr
96 with Huntington's disease (CAG repeats) and
myotonic dystrophy type 1 (CTG repeats).
97 anded rCUG and rCAG repeat RNAs expressed in
myotonic dystrophy type 1 (DM1) and spinocerebellar atax
98 Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are cau
99 d CCUG are the underlying genetic causes for
myotonic dystrophy type 1 (DM1) and type 2 (DM2), respec
100 sequence is considered a causative agent of
myotonic dystrophy type 1 (DM1) because of its ability t
101 nscript (CUG(exp)) is the causative agent of
myotonic dystrophy type 1 (DM1) by sequestering musclebl
102 man spinocerebellar ataxia type 8 (SCA8) and
myotonic dystrophy type 1 (DM1) CAG expansion transcript
103 disease (HD) FEN1 +/- heterozygous mice and
myotonic dystrophy type 1 (DM1) FEN1 +/- heterozygous mi
104 Background Patients with
myotonic dystrophy type 1 (DM1) increased their physical
105 A working hypothesis for the pathogenesis of
myotonic dystrophy type 1 (DM1) involves the aberrant se
106 Myotonic dystrophy type 1 (DM1) is a complex neuromuscul
107 The genetic basis of
myotonic dystrophy type 1 (DM1) is a CTG expansion in th
108 Myotonic dystrophy type 1 (DM1) is a CTG microsatellite
109 Myotonic Dystrophy type 1 (DM1) is a dominant neuromuscu
110 Myotonic dystrophy type 1 (DM1) is a dominantly inherite
111 Myotonic dystrophy type 1 (DM1) is a genetic disorder in
112 Myotonic dystrophy type 1 (DM1) is a genetic disorder li
113 Myotonic dystrophy type 1 (DM1) is a life-threatening an
114 Myotonic dystrophy type 1 (DM1) is a microsatellite expa
115 Myotonic dystrophy type 1 (DM1) is a multisystem neuromu
116 Myotonic dystrophy type 1 (DM1) is a multisystemic genet
117 Myotonic dystrophy type 1 (DM1) is a neuromuscular disor
118 Myotonic dystrophy Type 1 (DM1) is a rare genetic diseas
119 Myotonic dystrophy type 1 (DM1) is a triplet repeating d
120 Myotonic dystrophy type 1 (DM1) is an autosomal dominant
121 Myotonic dystrophy type 1 (DM1) is an autosomal dominant
122 Myotonic dystrophy type 1 (DM1) is an autosomal dominant
123 Myotonic dystrophy type 1 (DM1) is an incurable neuromus
124 Myotonic dystrophy type 1 (DM1) is an inherited dominant
125 Myotonic dystrophy type 1 (DM1) is an RNA dominant disea
126 Myotonic dystrophy type 1 (DM1) is an RNA-dominant disea
127 Myotonic dystrophy type 1 (DM1) is associated with expan
128 Myotonic dystrophy type 1 (DM1) is caused by a CTG expan
129 Myotonic dystrophy type 1 (DM1) is caused by a CTG expan
130 Myotonic dystrophy type 1 (DM1) is caused by a CTG trinu
131 Myotonic dystrophy type 1 (DM1) is caused by an expanded
132 Myotonic dystrophy type 1 (DM1) is caused by expansion o
133 Myotonic dystrophy type 1 (DM1) is caused by expansion o
134 Myotonic dystrophy type 1 (DM1) is caused by the expansi
135 Myotonic dystrophy type 1 (DM1) is one of the most varia
136 Myotonic dystrophy type 1 (DM1) is one such disorder tha
137 Myotonic dystrophy type 1 (DM1) is the most common form
138 ion hypothesis for the CTG expansion causing
myotonic dystrophy type 1 (DM1) located in the 3' noncod
139 The disease mechanism underlying
myotonic dystrophy type 1 (DM1) pathogenesis in skeletal
140 Accumulation of RNA CUG repeats in
myotonic dystrophy type 1 (DM1) patients leads to the in
141 In
myotonic dystrophy type 1 (DM1), dystrophia myotonica pr
142 splicing has become a molecular hallmark of
myotonic dystrophy type 1 (DM1), in which neonatal splic
143 ough cataract is a characteristic feature of
myotonic dystrophy type 1 (DM1), little is known of the
144 and GAA.TTC are integral to the etiology of
myotonic dystrophy type 1 (DM1), myotonic dystrophy type
145 In
myotonic dystrophy type 1 (DM1), somatic mosaicism of th
146 Myotonic dystrophy type 1 (DM1), the most common adult m
147 Among them is
myotonic dystrophy type 1 (DM1), the most common form of
148 Myotonic dystrophy type 1 (DM1), the most common form of
149 Myotonic dystrophy type 1 (DM1), the most common form of
150 Myotonic dystrophy type 1 (DM1), the most common muscula
151 Myotonic dystrophy type 1 (DM1), the most prevalent musc
152 In the hereditary degenerative disease
myotonic dystrophy type 1 (DM1), transcripts from the mu
153 In
myotonic dystrophy type 1 (DM1), triplet repeat expansio
154 date disease for RNAi therapy application is
myotonic dystrophy type 1 (DM1), which results from toxi
155 (hDMPK) gene products has been implicated in
myotonic dystrophy type 1 (DM1), yet the impact of distr
156 h are disrupted on loss of MBNL1 function in
myotonic dystrophy type 1 (DM1).
157 rophia myotonica protein kinase (DMPK) cause
myotonic dystrophy type 1 (DM1).
158 k CTG expansion (CTG(exp)) knockin models of
myotonic dystrophy type 1 (DM1).
159 S; trisomy 21) and the dementia component of
myotonic dystrophy type 1 (DM1).
160 als with the inherited multisystemic disease
myotonic dystrophy type 1 (DM1).
161 ting symptom experienced by individuals with
myotonic dystrophy type 1 (DM1).
162 d pathogenic role of expanded CUG repeats in
myotonic dystrophy type 1 (DM1).
163 ocess is impaired in patients afflicted with
myotonic dystrophy type 1 (DM1).
164 rationally designed, multi-target agents for
myotonic dystrophy type 1 (DM1).
165 METHODS AND We selected 855 patients with
myotonic dystrophy type 1 (women, 51%; median age, 37 ye
166 cause dominantly inherited diseases such as
myotonic dystrophy type 1 and 2 (DM1/2), Huntington's di
167 Friedreich ataxia,
myotonic dystrophy type 1 and 3 forms of intellectual di
168 detected in mouse models with DCM, including
myotonic dystrophy type 1 and CELF1 overexpression model
169 s previously characterized in the context of
myotonic dystrophy type 1 and epithelial-to-mesenchymal
170 se sequences are involved in the etiology of
myotonic dystrophy type 1 and Friedreich's ataxia, respe
171 xias and the initial clinical application in
myotonic dystrophy type 1 and Huntington's disease.
172 Myotonic dystrophy type 1 and type 2 (DM1 and DM2) are g
173 ress in elucidating the disease mechanism in
myotonic dystrophy type 1 and type 2.
174 Patients with adult
myotonic dystrophy type 1 are at high risk for arrhythmi
175 ng in the molecular and clinical features of
myotonic dystrophy type 1 as well as the screening of cl
176 epeats (CUG(exp)) are the causative agent of
myotonic dystrophy type 1 by sequestering MBNL1.
177 Up to one-third of patients with
myotonic dystrophy type 1 die suddenly.
178 Historically, patients with
myotonic dystrophy type 1 have not received the medical
179 Myotonic dystrophy type 1 is an autosomal dominant disor
180 Myotonic dystrophy type 1 is caused by the dysregulation
181 The average age of death in
myotonic dystrophy type 1 is in the fifth decade.
182 Myotonic dystrophy type 1 is the most prevalent muscular
183 he size of the CTG expansion in the blood of
myotonic dystrophy type 1 patients is associated with to
184 n contrast to the CUG-RNA hairpins formed by
myotonic dystrophy type 1 repeats, we found no evidence
185 umina sequencing in Huntington's disease and
myotonic dystrophy type 1 subjects, we show that rs55787
186 der than 18 years with genetically confirmed
myotonic dystrophy type 1 who were admitted to the Neuro
187 How this untranslated CTG expansion causes
myotonic dystrophy type 1(DM1) has been controversial.
188 been implicated in human diseases including
myotonic dystrophy type 1, Alzheimer's disease and multi
189 Among patients with
myotonic dystrophy type 1, an invasive strategy was asso
190 nine had myotonic dystrophy type 2, one had
myotonic dystrophy type 1, and 17 had no identified muta
191 (P = 0.003) in both Huntington's disease and
myotonic dystrophy type 1, and slower progression (P = 3
192 isease phenotype in Huntington's disease and
myotonic dystrophy type 1, and suggests a common DNA rep
193 le for causing neurological diseases such as
myotonic dystrophy type 1, but its binding mechanism rem
194 ples from individuals with one such disease,
myotonic dystrophy type 1, provides an opportunity to pa
195 f Friedreich ataxia, fragile X syndrome, and
myotonic dystrophy type 1, respectively.
196 dementia, fragile X tremor ataxia syndrome,
myotonic dystrophy type 1, spinocerebellar ataxia type 8
197 In
myotonic dystrophy type 1, the association between mutat
198 Similar to
myotonic dystrophy type 1, the poly(CUG)n RNA co-localiz
199 atrophy, amyotrophic lateral sclerosis, and
myotonic dystrophy type 1, were also reviewed.
200 Exon 2 is significantly reduced in
myotonic dystrophy type 1, whose symptoms include dement
201 uation, out of 1014 patients included in the
Myotonic Dystrophy Type 1-Heart Registry between January
202 disorders, including Huntington disease and
myotonic dystrophy type 1.
203 er onset of symptoms and is less common than
myotonic dystrophy type 1.
204 myotonica protein kinase (DMPK) gene causes
myotonic dystrophy type 1.
205 able therapeutic target for the treatment of
myotonic dystrophy type 1.
206 ive diseases, such as Huntington disease and
myotonic dystrophy type 1.
207 tracts in the size range that is typical for
myotonic dystrophy type 1.
208 n abnormalities in the neuromuscular disease
myotonic dystrophy type 1.
209 06 adult patients with genetically confirmed
myotonic dystrophy type 1.
210 expansion disorders Huntington's disease and
myotonic dystrophy type 1.
211 en implicated in the cardiac pathogenesis of
myotonic dystrophy type 1.
212 atrophy, amyotrophic lateral sclerosis, and
myotonic dystrophy type 1.
213 atrophy, amyotrophic lateral sclerosis, and
myotonic dystrophy type 1.
214 ranslated CCTG expansion in an intron causes
myotonic dystrophy type 2 (DM2) have uncovered a new typ
215 Myotonic dystrophy type 2 (DM2) is a genetic disorder ch
216 Myotonic dystrophy type 2 (DM2) is a multisystemic disor
217 Myotonic dystrophy type 2 (DM2) is an incurable neuromus
218 Myotonic dystrophy type 2 (DM2) is caused by a CCTG expa
219 The recent discovery that
myotonic dystrophy type 2 (DM2) is caused by an untransl
220 Myotonic dystrophy type 2 (DM2) is caused by the extreme
221 ponsible for the massive expansions found in
myotonic dystrophy type 2 (DM2) patients.
222 ribed but untranslated CCTG expansion causes
myotonic dystrophy type 2 (DM2), along with other discov
223 oops in r(CCUG)(exp), the causative agent of
myotonic dystrophy type 2 (DM2), and are transformed int
224 etiology of myotonic dystrophy type 1 (DM1),
myotonic dystrophy type 2 (DM2), and Friedreich's ataxia
225 so examined the similarly slowly progressing
myotonic dystrophy type 2 (DM2).
226 ofilm formation in Staphylococcus aureus and
myotonic dystrophy type 2 in human, respectively.
227 Myotonic dystrophy type 2 is a genetic neuromuscular dis
228 Myotonic dystrophy type 2 is caused by a (CCTG)/(CCUG)n
229 not well understood and the role of ZNF9 in
myotonic dystrophy type 2 pathogenesis has not been full
230 In comparison,
myotonic dystrophy type 2 tends to cause a milder phenot
231 We explored this question using
myotonic dystrophy type 2, a multisystemic disease thoug
232 irst intron of the ZNF9 gene associated with
myotonic dystrophy type 2, form slipped-strand DNA struc
233 s, 34 had sodium channel mutations, nine had
myotonic dystrophy type 2, one had myotonic dystrophy ty
234 l mutations, chloride channel mutations, and
myotonic dystrophy type 2.
235 The neuromuscular disease
myotonic dystrophy type I (DM1) affects multiple organ s
236 Myotonic dystrophy type I (DM1) exhibits distinctive dis
237 Myotonic dystrophy type I (DM1) is a disabling multisyst
238 Myotonic dystrophy type I (DM1) is a disabling neuromusc
239 Myotonic dystrophy type I (DM1) is a multisystemic autos
240 Myotonic dystrophy type I (DM1) is an RNA-mediated disea
241 They contain CUG repeats, relevant to
myotonic dystrophy type I, and CAG repeats associated wi
242 Molecular therapeutics for
myotonic dystrophy will probably bridge the translationa
243 ment for clinical screening of patients with
myotonic dystrophy with proactive and systematic managem
244 an skeletal actin (HSA)(LR) mice (a model of
myotonic dystrophy) of various ages.
245 ar ataxia, amyotrophic lateral sclerosis and
myotonic dystrophy) that involve mutations within the an
246 es of repeat instability and pathogenesis in
myotonic dystrophy, a neurological disorder caused by an
247 disease process raises the possibility that
myotonic dystrophy, among genetic disorders, may be unus
248 ts in Friedreich's ataxia, (CTG)n repeats in
myotonic dystrophy, and (CGG)n repeats in fragile X synd
249 sity in humans as may occur in, for example,
myotonic dystrophy, and possibly, the metabolically obes
250 leblind-like 1 (MBNL1), a gene implicated in
myotonic dystrophy, as a robust suppressor of multiorgan
251 ated with multiple human diseases, including
myotonic dystrophy, Fuchs endothelial corneal dystrophy,
252 Many neurological diseases, including
myotonic dystrophy, Huntington's disease and several spi
253 AA)n, are associated with diseases including
myotonic dystrophy, Huntington's disease, fragile X and
254 r phenotype reflects many of the features of
myotonic dystrophy, including muscle histological morpho
255 3' UTR mRNA reproduced cardinal features of
myotonic dystrophy, including myotonia, cardiac conducti
256 In the best studied example,
myotonic dystrophy, it appears that the main pathogenic
257 phasis on key updates in muscular dystrophy,
myotonic dystrophy, mitochondrial myopathy, spinal muscu
258 hronic progressive external ophthalmoplegia,
myotonic dystrophy, neurofibromatosis type 2, and basal
259 muscle cross-sectional area in patients with
myotonic dystrophy, preferentially in healthy-appearing
260 d the pathobiology of disease mechanisms for
myotonic dystrophy, spinal muscular atrophy, and fragile
261 In
myotonic dystrophy, the expression of expanded CUG repea
262 In
myotonic dystrophy, the lack of properly localized MBNL1
263 rnative splicing and have been implicated in
myotonic dystrophy, the most common form of adult onset
264 muscleblind function and the pathogenesis of
myotonic dystrophy, we generated Drosophila incorporatin
265 eases, including spinal muscular atrophy and
myotonic dystrophy, where defects of splicing or alterna
266 operties of potential therapeutic agents for
myotonic dystrophy, which is caused by sequestration of
267 In mammalian cells, the
myotonic dystrophy-related Cdc42-binding kinase possesse
268 sting a toxic RNA pathogenesis, as occurs in
myotonic dystrophy.
269 e diseases, including Huntington disease and
myotonic dystrophy.
270 uscle weakness and wasting characteristic of
myotonic dystrophy.
271 disease severity and therapeutic response in
myotonic dystrophy.
272 facioscapulohumeral muscular dystrophy, and
myotonic dystrophy.
273 hogenic feature of the neuromuscular disease
myotonic dystrophy.
274 ed and studied with respect to their role in
myotonic dystrophy.
275 lular localization is a central component of
myotonic dystrophy.
276 ead to muscle degeneration disorders such as
myotonic dystrophy.
277 des to treat Duchenne muscular dystrophy and
myotonic dystrophy.
278 g in corrective outcome for a mouse model of
myotonic dystrophy.
279 skeletal actin, long repeat) mouse model of
myotonic dystrophy.
280 ion disorders such as Huntington disease and
myotonic dystrophy.
281 on diseases such as Huntington's disease and
myotonic dystrophy.
282 ssues, including heart failure, diabetes, or
myotonic dystrophy.
283 onduction delay, two predominant features of
myotonic dystrophy.
284 causes symptoms in the neuromuscular disease
myotonic dystrophy.
285 bset of the cardiac dysfunctions observed in
myotonic dystrophy.
286 ical diseases such as Huntington disease and
myotonic dystrophy.
287 transition, resulting in the development of
myotonic dystrophy.
288 a potential drug target for the treatment of
myotonic dystrophy.
289 Myotonic muscular dystrophy (DM1) is the most common inh
290 Myotonic muscular dystrophy (MMD) is an autosomal-domina
291 Myotonic muscular dystrophy types 1 and 2 (DM1 and DM2,
292 In addition, the
myotonic mutations G200R and Y261C abolished potentiatio
293 variable presentation that included proximal
myotonic myopathy (PROMM) and type 2 DM (DM2) but withou
294 ypertrophic cardiomyopathy with dysrhythmia,
myotonic myopathy and hypotension, all distinctive muscl
295 All
myotonic pigs and their progenitors were homozygous rece
296 Interestingly, non-related, non-
myotonic pigs expressed transcriptional levels of an alt
297 as identical to the deleted X1 transcript of
myotonic pigs.
298 suggesting this may contribute to the end of
myotonic runs.
299 defects may increase excitability and cause
myotonic stiffness or may render fibres transiently inex
300 ks including myasthenia, periodic paralysis,
myotonic stiffness, seizures, headache, dyskinesia, or e